Lucinactant

Summary

Lucinactant (CHEMBL1963685) is an approved unknown; indicated across 5 conditions including meconium aspiration syndrome and acute respiratory distress syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 5 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1963685
Name	Lucinactant
Type	Unknown
Max phase	4

Also known as: ATI 02, ATI-02, Kl-surfactant, Lucinactant, Surfaxin, LUCINACTANT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
meconium aspiration syndrome	3	MONDO:0006851	EFO:1001037
acute respiratory distress syndrome	2	MONDO:0006502	EFO:1000637
newborn respiratory distress syndrome	2	MONDO:0700081	EFO:1000644
respiratory failure	2	MONDO:0021113	EFO:0009686
cystic fibrosis	2	MONDO:0009061	MONDO:0009061

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00004500	PHASE3	TERMINATED	Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome
NCT00215540	PHASE2	TERMINATED	SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
NCT00578734	PHASE2	COMPLETED	Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old
NCT00807235	PHASE2	TERMINATED	Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants
NCT00934362	PHASE2	COMPLETED	Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
NCT04389671	PHASE2	COMPLETED	The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).